NDAORALTABLETPriority Review
Approved
May 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
3/8 — Basic
Priority Review
VIOXX (rofecoxib) by Merck & Co.. Approved for postoperative pain, osteoarthritis, rheumatoid arthritis and 1 more indications. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIOXX (rofecoxib) is an oral nonsteroidal anti-inflammatory drug (NSAID) approved by the FDA in 1999 for treatment of osteoarthritis, rheumatoid arthritis, acute pain, and postoperative pain. As a selective COX-2 inhibitor, it reduces inflammation and pain by blocking cyclooxygenase-2 enzyme activity. The product targets patients seeking pain relief with a potentially improved gastrointestinal safety profile compared to traditional NSAIDs.
LOE Approaching
With LOE approaching, brand teams are managing a declining franchise; expect consolidation of commercial headcount and transition focus toward managed care and cost-containment strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (4)
Worked on VIOXX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.